Hypermethylation of the Micro-RNA 145 Promoter Is the Key Regulator for NLRP3 Inflammasome-Induced Activation and Plaque Formation

Zhong, Wei; Li, Bo; Xu, Yao; Yang, Ping; Chen, Rui; Wang, Zhongqun; Shao, Chen; Song, Juan; Yan, Jinchuan

doi:10.1016/j.jacbts.2018.06.004

Cited by 38 publications

(24 citation statements)

References 42 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High levels of this miR protect blood vessels from plaque formation and hypertension [74,75]. Hence, the methylation of miR-145 promoter downregulated the expression of the cis-regulated miR preventing its adverse action on the nuclear factor of activated T cells 1 (NFATc1) and CD137 [76]. As a result, VSMCs expressed more nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) that, in turn, activated interleukin 1β (IL-1β) secretion promoting intravascular inflammation [76].…”

Section: Non-coding Rna and Their Promoter Methylation In Cardiovascumentioning

confidence: 99%

“…Additionally, miR-145 regulates ubiquitin-like containing PHD and RING finger domains 1 (UHRF1), which interact with DNA methyltransferase 1 (DNMT1), suggesting an indirect link between miRNA modulation and DNA methylation [77]. DNMT1 was found to methylate miR-145 promoter realizing a negative feedback loop [76] (Figure 8).…”

Section: Non-coding Rna and Their Promoter Methylation In Cardiovascumentioning

confidence: 99%

See 1 more Smart Citation

Epigenetic Signaling and RNA Regulation in Cardiovascular Diseases

Mongelli

Atlante

Bachetti

et al. 2020

IJMS

View full text Add to dashboard Cite

RNA epigenetics is perhaps the most recent field of interest for translational epigeneticists. RNA modifications create such an extensive network of epigenetically driven combinations whose role in physiology and pathophysiology is still far from being elucidated. Not surprisingly, some of the players determining changes in RNA structure are in common with those involved in DNA and chromatin structure regulation, while other molecules seem very specific to RNA. It is envisaged, then, that new small molecules, acting selectively on RNA epigenetic changes, will be reported soon, opening new therapeutic interventions based on the correction of the RNA epigenetic landscape. In this review, we shall summarize some aspects of RNA epigenetics limited to those in which the potential clinical translatability to cardiovascular disease is emerging.

show abstract

Section: Non-coding Rna and Their Promoter Methylation In Cardiovascumentioning

confidence: 99%

Section: Non-coding Rna and Their Promoter Methylation In Cardiovascumentioning

confidence: 99%

Epigenetic Signaling and RNA Regulation in Cardiovascular Diseases

Mongelli

Atlante

Bachetti

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…The study also showed the reduced levels of the KLF4 in aortas treated with the miR‐145. However, hypermethylation of miR‐145 promoter proved that miR‐145 can be used to determine the prognosis of atherosclerosis development . The cluster comprising miR‐143 and miR‐145 (miR‐143/145) was found as crucial for vasculoprotective functions.…”

Section: Preclinical Studies Of Mirnas In Atherosclerosismentioning

confidence: 99%

Diagnostic and theranostic microRNAs in the pathogenesis of atherosclerosis

Shoeibi

2019

Acta Physiologica

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are a group of small single strand and noncoding RNAs that regulate several physiological and molecular signalling pathways. Alterations of miRNA expression profiles may be involved with pathophysiological processes underlying the development of atherosclerosis and cardiovascular diseases, including changes in the functions of the endothelial cells and vascular smooth muscle cells, such as cell proliferation, migration and inflammation, which are involved in angiogenesis, macrophage function and foam cell formation. Thus, miRNAs can be considered to have a crucial role in the progression, modulation and regulation of every stage of atherosclerosis. Such potential biomarkers will enable us to predict therapeutic response and prognosis of cardiovascular diseases and adopt effective preclinical and clinical treatment strategies. In the present review article, the current data regarding the role of miRNAs in atherosclerosis were summarized and the potential miRNAs as prognostic, diagnostic and theranostic biomarkers in preclinical and clinical studies were further discussed. The highlights of this review are expected to present opportunities for future research of clinical therapeutic approaches in vascular diseases resulting from atherosclerosis with an emphasis on miRNAs. K E Y W O R D Satherosclerosis, diagnosis, miRNA, prognosis, therapeutic approaches 2 of 24 | SHOEIBI Because miRNAs have a relatively high stability under the physiological conditions of mammals, they can be used as prognostic and diagnostic markers for diseases, such as atherosclerosis. This review aims to describe and summarize miRNA expression studies in model animal experiments and clinical practices related to atherosclerosis. The expressed pattern of miRNAs contributing to atherosclerosis at different stages of the atherosclerotic process in comparison with healthy arteries is also discussed.

show abstract

“…High levels of this miR protected blood vessels from plaque formation and hypertension [64,65]. Hence, the methylation of miR-145 promoter downregulated the expression of the cis-regulated miR preventing its adverse action on the nuclear factor of activated T cells 1 (NFATc1) and CD137 [66]. As a result, VSMCs expressed more nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) that, in turn, activated interleukin 1β (IL-1β) secretion promoting intravascular inflammation [66].…”

Section: Methylation At Ncrna Promoters and Its Consequences For Cvdsmentioning

confidence: 99%

“…Additionally, miR-145 regulates ubiquitin-like containing PHD and RING finger domains 1 (UHRF1), which interacts with DNA methyltransferase 1 (DNMT1), suggesting an indirect link between miRNA modulation and DNA methylation [67]. DNMT1 was found to methylate miR-145 promoter realizing a negative feedback loop [66] Moreover, low levels of miR145 allow the transduction of UTRF1 which is activator of DNMT1 that in turn methylates miR145 promoter activating a negative feedback loop.…”

Section: Methylation At Ncrna Promoters and Its Consequences For Cvdsmentioning

confidence: 99%

Epigenetic Signalling and RNA Regulation in Cardiovascular Diseases

Mongelli¹,

Atlante²,

Bacchetti³

et al. 2019

Preprint

View full text Add to dashboard Cite

RNA epigenetics is perhaps the most recent aspect of interest for translational epigeneticists. RNA modifications create such an extensive network of epigenetically driven combination whose role in physiology and pathophysiology is still far from being elucidated. Not surprisingly, some of the players determining changes into RNA structure are in common with those involved in DNA and chromatin structure regulation, while other molecules seem very specific to RNA. It is envisaged, then, that new small molecules, acting selectively on RNA epigenetic changes, will be reported soon, opening new therapeutic interventions based on the correction of the RNA epigenetic landscape. In this review, we shall summarize some aspects of RNA epigenetics limited to those in which the potential clinical translatability to cardiovascular disease is emerging.

show abstract

Hypermethylation of the Micro-RNA 145 Promoter Is the Key Regulator for NLRP3 Inflammasome-Induced Activation and Plaque Formation

Abstract: Visual Abstract

Cited by 38 publications

References 42 publications

Epigenetic Signaling and RNA Regulation in Cardiovascular Diseases

Epigenetic Signaling and RNA Regulation in Cardiovascular Diseases

Diagnostic and theranostic microRNAs in the pathogenesis of atherosclerosis

Epigenetic Signalling and RNA Regulation in Cardiovascular Diseases

Contact Info

Product

Resources

About